Skip to main content
search

News & Events

News

2022-12-01

BRIM Biotechnology, Inc. raises $20 million in Series E funding round
2022-11-16

BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
2022-11-01

BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
2022-08-25

BRIM Biotechnology Board of Directors approves seasoned equity offering of USD 18 million to accelerate phase 3 development of lead asset BRM421 for dry eye disease
2022-06-23

The road to regeneration: Could regenerative peptide therapy pave the way for new treatment methods for severe dry eye?
2022-06-22

BRIM Biotechnology enters Emerging Stock Market in Taiwan
2022-06-10

A Team Approach to Translational Science
2022-05-17

BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Disease
2022-04-13

A Peptide Approach to Regenerative Medicine
2022-04-04

Overcoming Challenges to Provide Affordable Treatments
Close Menu